All In Biotech

Drug Trial Radar · NCT03677141

A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

117

Actual

Start

Mar 8, 2019

Primary completion

Oct 12, 2023

Study completion Oct 12, 2023

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Sep 19, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).

Conditions

  • B-cell Non-Hodgkin Lymphoma

Interventions

  • MosunetuzumabDrug

    Participants will receive intravenous (IV) mosunetuzumab.

  • Polatuzumab VedotinDrug

    Participants will receive polatuzumab vedotin via IV.

  • RituxumabDrug

    Participants will receive rituxumab via IV.

  • CyclophosphamideDrug

    Participants will receive cyclophosphamide via IV.

  • DoxorubicinDrug

    Participants will receive doxorubicin via IV.

  • VincristineDrug

    Participants will receive vincristine via IV.

  • PrednisoneDrug

    Participants will receive oral prednisone.

  • TocilizumabDrug

    Participants will receive tocilizumab via IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)Time frame: 6-8 weeks after either C6D1 or last dose of study treatment

Locations

41 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Alabama Birmingham

    Birmingham, Alabama

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • University of California; Moores Cancer Center

    La Jolla, California

  • University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica

    Santa Monica, California

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • University of Miami Miller School of Medicine

    Miami, Florida

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • Rhode Island Hospital

    Providence, Rhode Island

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Scott and White Hospital; Cancer Center

    Temple, Texas

  • Medical College of Wisconsin, Inc.

    Milwaukee, Wisconsin

  • Uniklinikum Salzburg, LKH; Univ.Klinik f. Innere Medizin III der PMU

    Salzburg, Austria

  • LKH Steyr

    Steyr, Austria

  • Medizinische Universität Wien, Allgemeines Krankenhaus der Stadt Wien

    Vienna, Austria

  • Hanusch-Krankenhaus

    Vienna, Austria

  • CHU Henri Mondor; Service d'Oncologie Medicale

    Créteil, France

  • Centre Leon Berard

    Lyon, France

  • Hôpital Saint-Louis

    Paris, France

  • Centre Henri Becquerel- Centre de Lutte Contre le Cancer

    Saint-Herblain, France

  • Gustave Roussy

    Villejuif, France

  • Maria Sklodowska-Curie Memorial Cancer Centre

    Gliwice, Poland

  • Ma?opolskie Centrum Medyczne

    Krakow, Poland

  • Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka

    Słupsk, Poland

  • Instytut Hematologii i Transfuzjologii; Klinika Zaburze? Hemostazy i Chorób Wewn?trznych

    Warsaw, Poland

  • Katedra i Klinika Hematologii; Nowotworów Krwi i Transplantacji Szpiku

    Wroc?aw, Poland

  • Pusan National University Yangsan Hospital

    Gyeongsangnam-do, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, Spain

  • Hospital San Pedro de Alcantara; Servicio de Hematología

    Cáceres, Spain

  • Hospital General Universitario Gregorio Marañon

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Institut Catala d?Oncologia Hospital Germans Trias i Pujol

    Badalona, Barcelona, Spain

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.